Low Depth Epigenetic Mapping of Maturation Versus Retrodifferentiation in HepaRG Cells
Epigenomes · 02.06.2026 · 10 (2) · 36
DOI: 10.3390/epigenomes10020036 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epigenomes, online erschienen am 02.06.2026. Verfasst von Hector Hernandez-Vargas und 6 weiteren Autor:innen. Beteiligte Einrichtung: Genomics Consulting, 69500 Bron, France. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence Nationale de Recherches sur le Sida et les Hépatites Virales, Inserm, Centre National de la Recherche Scientifique.
Abstract (Originalsprache)
Background
Long-read, single-CpG-resolution sequencing is redefining the information-to-depth ratio in epigenomics. While conventional methylome analysis often requires high coverage, we propose a scalable pipeline designed to extract high-density regulatory logic from shallow sequencing data.
Methods
By utilizing the progenitor-like HepaRG cell line as a model for liver plasticity, we validated this framework across two divergent developmental trajectories: hepatic maturation and sphere-induced retrodifferentiation. Our technical approach combines CpG-centric enrichment and regional methylation aggregation to reconstruct regulatory landscapes from sparse data. Using long-read Nanopore sequencing, we mapped the dynamics of 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC).
Results
Our pipeline revealed that these trajectories are not inverse processes but engage distinct epigenetic strategies. Hepatic maturation is characterized by the accumulation of 5hmC that partially targets repressive heterochromatin (H3K9me3, H4K20me3) and pioneer factors such as FOXA2. In contrast, retrodifferentiation increases 5mC, potentially silencing adult regulators such as HNF1A via Polycomb-associated networks. In addition, aggregation-based analysis can distinguish widespread focal perturbations from a restricted subset of transcription factors that translate epigenetic changes into regional accessibility.
Conclusions
This study provides a scalable computational framework for investigating cellular fate transitions, proving that high-value epigenetic insights are attainable even at reduced sequencing depths.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Genomics Consulting, 69500 Bron, France.
- Institut NuMeCan (Nutrition, Metabolisms and Cancer), Inserm UMR_S 1317, Inrae UMR_A 1341, Université de Rennes, 35033 Rennes, France.
- INSERM Unité Mixte De Recherche 1350, PaThLiv IHU EVEREST, Université Claude-Bernard Lyon 1, 69003 Lyon, France.
- School of Science, Western Sydney University, Paramatta, NSW 2150, Australia.
ORCID-Profile: Hector Hernandez-Vargas, Kilian Petitjean, Marie-Pierre Lambert, Yoann Daniel, Isabelle Chemin, Chloe Goldsmith
Förderung
- Agence Nationale de Recherches sur le Sida et les Hépatites Virales
- Inserm
- Centre National de la Recherche Scientifique
- La Ligue Contre le Cancer
- University of Rennes
- Institut National de la Santé et de la Recherche Médicale
- Ligue contre le cancer-Comités d’Ille-et-Vilaine, des Côtes d’Armor et de Loire Atlantique
Zitieren
APA
Hernandez-Vargas, H., Petitjean, K., Lambert, M. P., Daniel, Y., Chemin, I., Corlu, A., & Goldsmith, C. (2026). Low Depth Epigenetic Mapping of Maturation Versus Retrodifferentiation in HepaRG Cells. Epigenomes, 10(2), 36. https://doi.org/10.3390/epigenomes10020036
Vancouver
Hernandez-Vargas H, Petitjean K, Lambert MP, Daniel Y, Chemin I, Corlu A, et al. Low Depth Epigenetic Mapping of Maturation Versus Retrodifferentiation in HepaRG Cells. Epigenomes. 2026;10(2):36. doi:10.3390/epigenomes10020036
BibTeX
@article{HernandezVargas2026,
author = {Hernandez-Vargas, Hector and Petitjean, Kilian and Lambert, Marie-Pierre and Daniel, Yoann and Chemin, Isabelle and Corlu, Anne and Goldsmith, Chloe},
title = {Low Depth Epigenetic Mapping of Maturation Versus Retrodifferentiation in HepaRG Cells},
journal = {Epigenomes},
year = {2026},
volume = {10},
number = {2},
pages = {36},
doi = {10.3390/epigenomes10020036}
}
EUVIMED